Drug intelligence / Profile preview

cyclophosphamide + docetaxel + epirubicin + gemcitabine

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), docetaxel (a taxane), epirubicin (an anthracycline), and gemcitabine (a nucleoside analog). This regimen has been studied primarily in breast cancer treatment, including high-risk early breast cancer and metastatic breast cancer. Clinical trials have examined various sequences and combinations of these agents, with some studies showing that the specific order of administration can impact both efficacy and toxicity profiles.

Targets

DNARNR (Ribonucleotide reductase)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on cyclophosphamide + docetaxel + epirubicin + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + docetaxel + epirubicin + gemcitabine.

Explore the full profile